替格瑞洛治疗急性冠脉综合征患者的临床疗效观察

廖菽丹1 ，王昌育2 ，张涛1

（1.西安市中心医院心内科，陕西 西安，710032；2.西安市第三医院心内科，陕西 西安，710032）

浏览次数：86次 下载次数：342次

摘要：

目的 评价替格瑞洛在急性冠脉综合征（ACS）患者孕CI术中的临床应用效果。方法 入选ACS并行PCI治疗的患者76例，随机分为氯吡格雷组、替格瑞洛组，每组38例，比较两组治疗效果。结果 入组后30 d 内，两组的心血管事件和副 作用发生情况比较，差异无统计学意义（P>0.05）。随访1个月，替格瑞洛组ADP诱导的血小板聚集抑制率为（58.4± 14.7）%，氯吡格雷组为（56.8±14.9）%，其中，氯吡格雷组有3例患者ADP诱导的血小板聚集抑制率<30%，存在氯吡格雷抵抗。结论 相较于氯吡格雷，替格瑞洛可以提高ADP 诱导的血小板聚集抑制率，保证ACS患者PCI抗栓指标合格。

关键词：氯吡格雷；替格瑞洛；ACS；ADP 诱导的血小板聚集抑制率

中图分类号：R541.4文献标志码：A文章编号：2096-1413(2017)28-0003-03

Clinical therapeutic effect observation of ticagrelor in the treatment of patients with acute coronary syndrome
LIAO Shu-dan 1, WANG Chang-yu 2, ZHANG Tao 1
(1. Department of Cardiovascular, Xi``an Central Hospital, Xi``an 710032; 2. Department of Cardiovascular, Xi``an No.3 Hospital, Xi``an 710032, China)

ABSTRACT: Objective To evaluate the clinical effect of ticagrelor in the treatment of patients with acute coronary syndrome (ACS) undergoing PCI. Methods A total of 76 cases of ACS patients who needed PCI were selected and randomly divided into ticagrelor group and clopidogrel group, the therapeutic effects of the two groups were compared. Results Within 30 days after admission, there was no significant difference in incidence of cardiovascular and adverse events (P<0.05).The patients were followed up for 1 months, ADP induced platelet aggregation inhibition rate in the ticagrelor group was (56.8±14.9)%, while that in the clopidogrel group was (58.4±14.7)%. In clopidogrel group, there were 3 patients had ADP induced platelet aggregation inhibition rate <30% , and it showed clopidogrel resistance. Conclusion Compared with clopidogrel, ticagrelor can effectively improve the ADP induced platelet aggregation inhibition rate, and ensure the antithrombotic standard in patients with acute coronary syndrome after PCI.
KEYWORDS: clopidogrel; ticagrelor; ACS; ADP induced platelet aggregation inhibition rate

参考文献：
[1] DAVI G,PATRONO C.Platelet activation and atherothrombosis [J].N Engl J Med,2007,357(24):2482-2494.
[2] 王伟娜.血小板聚集试验及其临床应用进展[J].临床军医杂志,2015,43(11):1204-1206.
[3] WANG L,WANG X,CHEN F.Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents[J].Drugs RD,2010,10(4):219-224.
[4] BLIDEN KP,DICHIARA J,TANTRY US,et al.Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current an原tiplatelet therapy adequate?[J].J Am Coll Cardiol,2007,49(6):657-666.
[5] WALLENTIN L,BECKER RC,BUDAJ A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes [J].N Engl J Med, 2009,361(11):1045-1057.
[6] SHOWKATHALI R,NATARAJAN A.Antiplatelet and antithrombin strategies in acute coronary syndrome: state -of -the -art review [J].Curr Cardiol Rev,2012,8(3): 239-249.
[7] 龚志刚.氯吡格雷抵抗[J].中华现代内科学杂志,2008,5(3):228-230.
[8] 中华医学会心血管病学分会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志,2012,40(5):353-367.
[9] NGUYEN TA,DIODATI JG,PHARAND C.Resistance to clopidogrel: a review of the evidence[J].J Am Coll Cardiol,2005,45(8):1157-1164.
[10] LOMBO B,DEZ JG.Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes[J].Core Evid,2011 (6):31-42.
[11] STEG PG,JAMES SK,ATAR D,et al.ESC guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation[J].Eur Heart J,2012,33(20):2569-2619.
[12] JEONG YH,BLIDEN KP,ANTONINO MJ,et al.Usefulness of the Verify Now P2Y12 assay to evaluate the anti -platelet effects of ticagrelor and clopidogrel therapies[J].Am Heart J,2012,164(1):35-42.
[13] JAMES S,AKERBLOM A,CANNON CP,et al.Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial[J].Am Heart J,2009,157(4):599-605.
[14] 任艳琴,郭任维,李建国.替格瑞洛在急性冠脉综合征经皮冠状 动脉介入治疗患者中的短期疗效观察[J].临床医药实践,2017,26(4):270-273.